Results 211 to 220 of about 626,377 (227)

PCSK9 inhibitors and cardiovascular outcomes

Expert Opinion on Biological Therapy, 2020
Peter Bramlage, Julian Friebel
exaly  

PCSK9 inhibitors in clinical practice: Delivering on the promise?

Atherosclerosis, 2018
Merel Hartgers, Erik Stroes, Katrien Santema   +2 more
exaly  

The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors

Current Pharmaceutical Design, 2019
Eleni Theocharidou, Alexandros Sachinidis, Olga Giouleme   +2 more
exaly  

Heterocyclic inhibitors of PCSK9

2018
TREUTLEIN HERBERT, ZENG JUN, DIXON IAN, JAMES IAN, PALMER JAMES T   +4 more
openaire   +3 more sources

The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia

Journal of Cardiovascular Pharmacology and Therapeutics, 2018
C Michael White
exaly  

CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism

Atherosclerosis, 2014
Amar Bahadur Singh
exaly  

Familial hypercholesterolaemia: PCSK9 inhibitors are coming

The Lancet, 2015
Raul D, Santos, Gerald F, Watts
openaire   +2 more sources

Oral PCSK9 inhibitor is effective and safe

Nature Reviews Cardiology, 2023
openaire   +2 more sources

Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review

Heart Failure Reviews, 2019
Nicola Luigi Bragazzi, Masoud Behzadifar, Hossein Safari   +2 more
exaly  

Piperidine compounds as PCSK9 inhibitors

2018
WU CHENGDE, YAN JIE, XU WENJIE, YU TAO, LI NING, CHEN SHUHUI   +5 more
openaire   +2 more sources